Screener
Incyte
INCYIncyte is a global biopharmaceutical company specializing in the discovery, development, and commercialization of proprietary therapeutics.
Earnings
Next report
Oct 27, 2026 (in 2 months)Revenue estimate$1.5B
EPS estimate-$2.83
Segments
Competitors
By market cap
By revenue growth
Profile
Incyte is a global biopharmaceutical company specializing in the discovery, development, and commercialization of proprietary therapeutics. The company focuses on three core therapeutic areas: Hematology, Oncology, and Inflammation and Autoimmunity. Its primary value proposition lies in its ability to bring first-in-class and best-in-class treatments to market for rare blood cancers and immune-related conditions.
Competitive position
A leading player in the JAK inhibitor space with a dominant market position in myelofibrosis and polycythemia vera treatments.
GeographiesUnited States, Europe, Japan, Canada
Customer segmentsPatients with rare diseases, Healthcare providers, Specialty distributors
Business modelR&D-based drug development, Direct commercialization, Licensing and royalties
SuppliersContract manufacturing organizations, Raw material suppliers, Clinical research organizations
CustomersSpecialty pharmacy providers, Pharmaceutical wholesalers, Government healthcare programs, Private insurers
CountryUnited States of America
Listed1993
Employees2.5K
CEOWilliam J. Meury
SectorHealthcare
IndustryBiotechnology
Websiteincyte.com
FilingsSEC EDGAR
FAQ
- What is Incyte's market cap?
- Incyte (INCY) has a market capitalization of $26.0B and trades on NASDAQ.
- What is Incyte's revenue and profitability?
- Incyte generated $5.8B in trailing twelve-month revenue with net income of $1.6B, representing a net margin of 27.7%. Gross margin stands at 92.6%, with free cash flow of $2.0B. These figures are based on the Q2 2026 filing.
- Who are Incyte's competitors?
- Incyte's key competitors include Gilead Sciences, Bristol-Myers Squibb, Pfizer, and others. These companies compete in similar markets and product categories.
- Who does Incyte partner with?
- Incyte's notable partners include Novartis, MorphoSys, Syndax Pharmaceuticals, and others.
- What subsidiaries does Incyte have?
- Incyte's subsidiaries include Incyte Biosciences Europe Sàrl, ARIAD Pharmaceuticals (European Operations).
- Where is Incyte headquartered?
- Incyte is headquartered in United States of America and employs approximately 2,524 people. It has been publicly traded since 1993.
